Evidence map›Paper›PMID 36655745›Full record

ArticleJournal of comparative effectiveness research2023

Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective.

Brian Murray, Jennifer Miles-Thomas, Amy J Park, Victor B Nguyen, Amy Tung, Patrick Gillard, Anjana Lalla, Victor W Nitti, Christopher J Chermansky

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Brian MurrayCapital Region Urological Surgeons, 319 S Manning Blvd #106, Albany, NY 12208, USA.
Jennifer Miles-ThomasEastern Virginia Medical School, 225 Clearfield Ave, Virginia Beach, VA 23462, USA.
Amy J ParkCleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
Victor B NguyenCurta, Inc., 4872 Beach Dr SW, Seattle, WA 98116, USA.
Amy TungAllergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USA.
Patrick GillardAllergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USA.
Anjana LallaAllergan, an AbbVie company, 2525 Dupont Drive, Irvine, CA 92612, USA.
Victor W NittiDavid Geffen School of Medicine at UCLA, 300 Stein Plaza Driveway, Los Angeles, CA 90095, USA.
Christopher J ChermanskyUniversity of Pittsburgh Medical Center Magee Womens Hospital, 300 Halket St, Suite 2541, Pittsburgh, PA 15213, USA.
Allergan (United States) · USClearfield (United States) · USCleveland Clinic · USUniversity of California, Los Angeles · USUniversity of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Botulinum Toxins, Type AUrinary Bladder, OveractiveAgedCholinergic AntagonistsCost-Benefit AnalysisHumansMedicareQuality-Adjusted Life YearsUnited StatesBotulinum Toxins, Type ACholinergic Antagonistsanticholinergiccost–effectivenessMarkov modelonabotulinumtoxinAoveractive bladderquality-adjusted life-yearrechargeable sacral nerve stimulationβ3-adrenoceptor agonist

Identifiers

PMID36655745
PMCPMC10288955
OpenAlexW4317479973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.